Dupilumab significantly reduced itch severity and urticaria activity in chronic spontaneous urticaria patients unresponsive to antihistamines.
2
The LIBERTY-CSU CUPID-C trial involved 151 patients aged 6 to 80 years, demonstrating dupilumab's efficacy over a 24-week period.
3
At week 24, 70% of dupilumab patients achieved a 5-point reduction in itch severity, compared to 52% in the placebo group.
4
Safety profiles were similar between dupilumab and placebo, with common adverse events including nasopharyngitis and injection-site reactions.
5
The study confirmed dupilumab's benefits for patients with CSU, reinforcing its clinical efficacy and safety for those resistant to standard treatments.
